Association between secondary mutations in human immunodeficiency virus type 1 protease and therapeutic outcome.

Open Access
Publisher Website
Google Scholar
Abstract
To the Editor–Perno et al. [1] report that the number of pretherapy secondary mutations in human immunodeficiency virus (HIV) type 1 protease and the combination ofmutations at codons 10 and 36 are associated with poorer outcome for patients commencing protease inhibitor (PI)-based combination antiretroviral therapy (CART).We have a number of concerns relating to these findings.